Law360, London: Allianz has beaten a theatre operator's attempt to revive a coronavirus (COVID-19) business interruption claim, as an appeals court ruled on 28 October 2024 that the insurer's policy did not cover losses caused by government-mandated lockdowns.

ARCHIVED: This archived Practice Note is not maintained and is for background information only. This Practice Note considers the original Coronavirus (COVID-19) Job Retention Scheme (CJRS), first announced by the government on 20 March 2020 that applied between 1 March and 30 June 2020. For information on: • the extended CJRS that applies between 1 May and 30 September 2021, see Practice Note: Coronavirus Job Retention Scheme (extended version 1 May to 30 September 2021) [Archived] • the extended CJRS that applied between 1 November 2020 and 30 April 2021, see Practice Note: Coronavirus Job Retention Scheme (extended version 1 November 2020 to 30 April 2021) [Archived] • the revised CJRS that applied between 1 July and 31 October 2020, see Practice Note: Coronavirus Job Retention Scheme (extended version 1 July to 31 October 2020) [Archived] The Coronavirus Job Retention Scheme is a temporary scheme, initially announced to be in place for three months starting from 1 March 2020, but HM Treasury announced, on 17 April 2020, that

A number of competition authorities around the world are amending their operations due to the impact of the coronavirus (COVID-19) outbreak. The table below summarises the situation in relation to merger control procedures in highlighted jurisdictions. Note–only jurisdictions that are known to have amended their procedures due to the coronavirus outbreak are included; unless stated below, there are no known changes to procedure. For coronavirus (COVID-19) related developments in relation to antitrust investigations, exceptions/exemptions and State aid investigations, see Coronavirus (COVID-19)—global behavioural, exemptions and State aid case tracker. Jurisdiction Merger control regime status update Albania The Competition Authority had postponed all meetings and hearings scheduled until 31/03/2020 to April 2020. All investigations were suspended until 31/03/2020. As of mid-April, the Competition Authority begun issuing merger clearance decisions.Merger notifications can be submitted via email. Angola All documents should be sent to the ARC by email; no face-to-face contact is possible. Argentina The CNDC had suspended all investigation deadlines; the suspension ended and deadlines resumed on 26/10/2020 Notifications to be submitted by email or

ARCHIVED: This Practice Note has been archived and is not maintained. This Practice Note focuses on the implications for PI and clinical negligence practitioners in the light of temporary rules and guidance introduced following the coronavirus (COVID-19) pandemic. This Practice Note should be read in conjunction with Practice Notes: • Coronavirus (COVID-19) implications for dispute resolution [Archived] • Coronavirus (COVID-19) civil court specific guidance—dispute resolution [Archived] Case management of personal injury claims See also Practice Note: Coronavirus (COVID-19) implications for dispute resolution [Archived]—Case progression and management. The Association of Personal Injury Lawyers (APIL) and Forum for Insurance Lawyers (FOIL) published guidance on best practice to assist claimant and defendant lawyers handling personal injury claims during the coronavirus pandemic. This agreement was first introduced on 31 March 2020 and continues to apply (subject to periodic review). The guidance is of course subject to compliance with the CPR and includes the following. Communication Practitioners should engage with their counterparts by telephone and/or email with a view to resolving disputes

Insurance & Reinsurance analysis: The High Court’s decision in the Financial Conduct Authority’s (FCA) coronavirus (COVID-19) business interruption (BI) test case will be published on 15 September 2020. The decision is widely expected to be appealed, whatever the High Court decides. Accordingly, the wait for the legal certainty needed to adjust and settle valid coronavirus BI claims is set to continue for several months yet. Pamela Freeland of Weightmans and the Lexis®PSL Insurance & Reinsurance team consider the implications of this impasse for coronavirus BI claims advanced in other forums, such as the Financial Ombudsman Service (FOS), arbitration or separate actions in the County Court and the High Court—all the time while the coronavirus saga continues to unfold and produce new conundrums, such as the gradual withdrawal of government support through the coronavirus job retention scheme. We also take a step back and consider the essence of the parties’ respective positions on the critical issue of causation, and the implications that the courts’ final reckoning on the issue might have for insurance law.

ARCHIVED: This Practice Note has been archived and is not maintained. During the coronavirus (COVID-19) pandemic, the UK government implemented a series of measures to support individuals and businesses adversely affected by the pandemic. Several of these measures involved the receipt of funds directly from government or local government that were not expected to be paid back, ie grants rather than loans. For more detail on these schemes, see Practice Note: Coronavirus (COVID-19)—tax implications [Archived]. Guidance relating to these schemes indicated that the recipients should treat these grants as taxable income because the grant was, in effect, replacing business income that would otherwise have arisen. On 29 May 2020, the government published draft legislation, tax information and impact note and explanatory notes for consultation. The legislation was ultimately enacted as section 106 of and Schedule 16 to Finance Act 2020 (FA 2020). The purposes of the legislation were: • to treat COVID-19 support payments as income where the business was within the scope of income tax or corporation tax • to enable

The Health Protection (Coronavirus Restrictions) (No 5) (Wales) Regulations 2020, SI 2020/1609 came into force on 18 December 2020 in exercise of the powers conferred by the Public Health (Control of Disease) Act 1984, and expire at the end of the day on 26 November 2021. The purpose of the Regulations are to set out various provisions and restrictions arising out of the coronavirus (COVID-19) pandemic. The Health Protection (Coronavirus Restrictions) (No 5) (Wales) Regulations 2020, SI 2020/1609, Pt 3 (SI 2020/1609, reg 5) sets out the requirement for a person to isolate where a person tests positive for coronavirus or has close contact with such a person. ‘Close contact’ is defined by SI 2020/1609, reg 5(1) as meaning contact that a contact tracer considers may lead to a risk of infection or contamination with coronavirus,

ARCHIVED: This Practice Note has been archived and is not maintained. This Practice Note tracks the developments and updates on coronavirus (COVID-19) that relate to the life sciences sector in the UK. For coronavirus developments of interest to the life sciences sector in the EU, including those which may have applied to the UK until the end of the Brexit transition period, and internationally, see Practice Note: Coronavirus (COVID-19)—EU life sciences tracker [Archived]. Jump to • Research and development of medicines and vaccines • IP waiver • Clinical trials • Regulation of medical devices • Regulation of vaccines, medicinal products and blood • Post-authorisation vigilance of medicines and vaccines • Supply of vaccines, medicines and medical products • Actions on falsified and unlicensed medicines, off-label use of medical devices • mHealth and data protection For a discussion on: • the impact of the coronavirus pandemic on the UK and EU regulatory frameworks, see Practice Note: Coronavirus (COVID-19)—regulatory implications for the UK and European life sciences industry [Archived] • what life sciences companies

UPDATE: Since this Q&A was first published on 3 April 2020, the HMRC guidance for employers: Claim for your employees’ wages through the coronavirus job retention scheme and guidance for employees: Check if your employer can use the coronavirus job retention scheme (first published on 26 March) has been updated on 4 April, 9 April and 15 April 2020. For information on the position as at 15 April 2020, see: Update (15 April 2020) below. For further information on these updates, see: • HMRC publishes updated employer and employee guidance on Coronavirus (COVID-19) job retention scheme • HMRC publishes second update to employer and employee guidance on Coronavirus (COVID-19) Job Retention Scheme, and • Treasury gives legal effect to Coronavirus Job Retention Scheme and updates guidance

This Practice Note is archived and no longer maintained. The table below shows the expiry of various support measures as applicable to Scotland (as part of the UK or in its own right, as indicated by the last column). September 2021 Date Event Scope 30 September 2021 Temporary restrictions on winding-up petitions and statutory demands expire and are replaced by new measures from 1 October 2021 (see below).See Practice Note: Corporate Insolvency and Governance Act 2020—temporary changes to corporate statutory demands and winding-up petitions [Archived], Corporate Insolvency and Governance Act 2020 (Coronavirus) (Extension of Relevant Period) (No. 2) Regulations, SI 2021/718 and Corporate Insolvency and Governance Act 2020 (Coronavirus) (Amendment of Schedule 10) (No. 2) Regulations 2021, SI 2021/1091. UK 30 September 2021 Expiry of the provision allowing more than one moratorium on diligence in any 12-month period.See Coronavirus (Extension and Expiry) (Scotland) Act 2021 Scotland 30 September 2021 The relaxation of eligibility criteria for companies applying for a moratorium expires (Corporate Insolvency and Governance Act

Law360, London: An insurance company has rejected claims from the Hollywood Bowl chain seeking at least £32.5m for interruption caused by coronavirus (COVID-19), arguing the restrictions that lockdowns entailed were not covered by the policy's wording.

This Archived Practice Note outlines the general base-line coronavirus (COVID-19) restrictions, including the modified regional tiered restrictions and the national restrictions in force in England until 19 July 2020, that applied to business premises, including premises licensed for the sale of food and drink, alcohol or entertainment until all formal restrictions were lifted. The government recommends continuing caution but formal restrictions have been removed with the warning that they may need to be reintroduced if health circumstances require it. The government measures to help prevent the spread of coronavirus (COVID-19) have changed significantly during the course of the pandemic from the national lockdown to taking more nuanced action in areas of increased transmission, so keeping track can be difficult for practitioners and their clients. This Practice Note aims to provide a reference point for the current restrictions in force in England. For the national restrictions during the initial response to the pandemic, see Archived Practice Note: Impact of coronavirus (COVID-19) on Licensing [Archived]. Roadmap out of national lockdown On